1798 related articles for article (PubMed ID: 22786462)
1. Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine.
Daitch J; Frey ME; Silver D; Mitnick C; Daitch D; Pergolizzi J
Pain Physician; 2012 Jul; 15(3 Suppl):ES59-66. PubMed ID: 22786462
[TBL] [Abstract][Full Text] [Related]
2. Conversion from high-dose full-opioid agonists to sublingual buprenorphine reduces pain scores and improves quality of life for chronic pain patients.
Daitch D; Daitch J; Novinson D; Frey M; Mitnick C; Pergolizzi J
Pain Med; 2014 Dec; 15(12):2087-94. PubMed ID: 25220043
[TBL] [Abstract][Full Text] [Related]
3. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
4. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
Sorge J; Sittl R
Clin Ther; 2004 Nov; 26(11):1808-20. PubMed ID: 15639693
[TBL] [Abstract][Full Text] [Related]
5. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study.
Sittl R; Likar R; Nautrup BP
Clin Ther; 2005 Feb; 27(2):225-37. PubMed ID: 15811486
[TBL] [Abstract][Full Text] [Related]
6. Opioid addicts at admission vs. slow-release oral morphine, methadone, and sublingual buprenorphine maintenance treatment participants.
Giacomuzzi S; Kemmler G; Ertl M; Riemer Y
Subst Use Misuse; 2006; 41(2):223-44. PubMed ID: 16393744
[TBL] [Abstract][Full Text] [Related]
7. Effects of intravenous patient-controlled analgesia with buprenorphine and morphine alone and in combination during the first 12 postoperative hours: a randomized, double-blind, four-arm trial in adults undergoing abdominal surgery.
Oifa S; Sydoruk T; White I; Ekstein MP; Marouani N; Chazan S; Skornick Y; Weinbroum AA
Clin Ther; 2009 Mar; 31(3):527-41. PubMed ID: 19393843
[TBL] [Abstract][Full Text] [Related]
8. Opioid use by patients in an orthopedics spine clinic.
Mahowald ML; Singh JA; Majeski P
Arthritis Rheum; 2005 Jan; 52(1):312-21. PubMed ID: 15641058
[TBL] [Abstract][Full Text] [Related]
9. Switching from high doses of pure μ-opioid agonists to transdermal buprenorphine in patients with cancer: a feasibility study.
Lundorff L; Sjøgren P; Hansen OB; Jonsson T; Nielsen PR; Christrup L
J Opioid Manag; 2013; 9(4):255-62. PubMed ID: 24353018
[TBL] [Abstract][Full Text] [Related]
10. When opioids fail in chronic pain management: the role for buprenorphine and hospitalization.
Berland DW; Malinoff HL; Weiner MA; Przybylski R
Am J Ther; 2013; 20(4):316-21. PubMed ID: 23584313
[TBL] [Abstract][Full Text] [Related]
11. Opioid agonist doses for oxycodone and morphine dependence: Findings from a retrospective case series.
Nielsen S; Bruno R; Degenhardt L; Demirkol A; Lintzeris N
Drug Alcohol Rev; 2017 May; 36(3):311-316. PubMed ID: 27273511
[TBL] [Abstract][Full Text] [Related]
12. A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain.
Mitra F; Chowdhury S; Shelley M; Williams G
Pain Med; 2013 Jan; 14(1):75-83. PubMed ID: 23320402
[TBL] [Abstract][Full Text] [Related]
13. Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients.
Freye E; Anderson-Hillemacher A; Ritzdorf I; Levy JV
Pain Pract; 2007 Jun; 7(2):123-9. PubMed ID: 17559481
[TBL] [Abstract][Full Text] [Related]
14. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study.
Sittl R; Nuijten M; Nautrup BP
Clin Ther; 2005 Jul; 27(7):1022-31. PubMed ID: 16154481
[TBL] [Abstract][Full Text] [Related]
15. Low-dose 7-day transdermal buprenorphine in daily clinical practice - perceptions of elderly patients with moderate non-malignant chronic pain.
Uberall MA; Müller-Schwefe GH
Curr Med Res Opin; 2012 Oct; 28(10):1585-95. PubMed ID: 22978772
[TBL] [Abstract][Full Text] [Related]
16. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
[TBL] [Abstract][Full Text] [Related]
17. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
Simpson DM; Messina J; Xie F; Hale M
Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
[TBL] [Abstract][Full Text] [Related]
18. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials.
Likar R; Kayser H; Sittl R
Clin Ther; 2006 Jun; 28(6):943-52. PubMed ID: 16860176
[TBL] [Abstract][Full Text] [Related]
19. Buprenorphine for chronic pain.
Calderon R; Copenhaver D
J Pain Palliat Care Pharmacother; 2013 Dec; 27(4):402-5. PubMed ID: 24245573
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and pharmacodynamic properties of buprenorphine after a single intravenous administration in healthy volunteers: a randomized, double-blind, placebo-controlled, crossover study.
Escher M; Daali Y; Chabert J; Hopfgartner G; Dayer P; Desmeules J
Clin Ther; 2007 Aug; 29(8):1620-31. PubMed ID: 17919544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
